Core Insights - Plus Therapeutics, Inc. has renewed its Master Services Agreement with Telix IsoTherapeutics Group, ensuring a reliable supply of cGMP Re-186, a key radioisotope for its lead candidate Rhenium (186Re) Obisbemeda [1][2] Group 1: Agreement Details - The renewed agreement enhances Plus Therapeutics' supply chain strategy by securing Re-186 through IsoTherapeutics and utilizing SpectronRx for final drug manufacturing, establishing a scalable supply chain for late-stage clinical trials and future commercial needs [2][7] - The focus of the agreement includes the production of aluminum perrhenate and the final processing of cGMP Re-186, enabling just-in-time manufacturing to support the overall supply chain [2][7] Group 2: Product Overview - Rhenium (186Re) Obisbemeda is an injectable radiotherapy designed for targeted high-dose radiation delivery in CNS tumors, aiming to optimize patient outcomes by reducing off-target risks compared to existing therapies [3] - The product is currently being evaluated in clinical trials for recurrent glioblastoma and leptomeningeal metastases, with support from the National Cancer Institute and a $17.6 million grant from the Cancer Prevention & Research Institute of Texas [3] Group 3: Company Background - Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for challenging CNS cancers, with a pipeline that includes recurrent glioblastoma and leptomeningeal metastases [4] - The company has established a strategic supply chain through partnerships to facilitate the development, manufacturing, and potential commercialization of its products [4]
Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply